Ambryon Biosciences

CAR-T Long Term Follow Up (LTFU) Study

Phase 3 single-group long-term follow-up study (PAVO) of up to 1,105 patients previously treated with lentiviral-based CAR-T cells in Novartis or University of Pennsylvania trials, monitoring delayed adverse events, replication competent lentivirus and CAR transgene persistence for 15 years. Recruiting; no results reported.

StatusRecruiting
PhasePhase 3
Enrollment1105
Start Date2015-11-02
Primary Completion Date2039-04-18

Results Summary

No results have been posted to ClinicalTrials.gov or published in a paper linked to this trial. The registered primary outcome is the percentage of patients with new secondary malignancies, new serious infections, new serious neurologic disorders, new or exacerbated rheumatologic or autoimmune disorders, or new hematologic disorders, assessed up to year 15. The study is still recruiting.

Design Implications

The design itself supports a few lessons. Regulators expect 15 years of follow-up for integrating lentiviral CAR-T products, so a new lentiviral cell therapy needs a long-term follow-up protocol, with consent for roll-over at the end or early discontinuation of the treatment study, planned from the start. Routine RCL testing by VSV-G assay and quantitative PCR for CAR transgene persistence belong in that protocol, as do monitoring for secondary malignancy and autoimmune events and growth and puberty assessments for children. Because this study pools many CAR-T products and diseases in one single-arm cohort, product-specific safety signals need the parent trial identifiers to be recorded.

Rationale

Lentiviral vectors integrate into the genome of the transduced T cells, so health authorities require long-term follow-up of patients treated with integrating-vector gene therapy products. This study follows patients for 15 years after their last infusion of lentiviral-based CAR-T cells (for example CTL019) to detect delayed adverse events, including secondary malignancies, serious infections, neurologic, autoimmune and hematologic disorders. It also tests for replication competent lentivirus (RCL) and measures CAR transgene persistence in blood by quantitative PCR, B- and T-lymphocyte counts and long-term efficacy.

Limitations

No results are available, so the study supports no efficacy or safety conclusion yet. It is single-arm and open-label with no comparator, enrolls patients from many parent CAR-T trials and diseases under one registry condition, and its enrollment of 1,105 is an estimate. Primary completion is not expected until 2039.

Registry record

Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.

Official TitleLong Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Primary OutcomesPercentage of patients with certain events (see description)
Registry Last Updated2026-10-02
Minimum Age0 Years
Modalitiescell_therapy, gene_therapy
Maximum Age100 Years
Intervention NamesPreviously treated CAR-T patients
AllocationNot Applicable
MaskingNone
Primary PurposeOther
Has ResultsNo
AcronymPAVO
Enrollment TypeEstimated
CountriesUnited States, Australia, Austria, Belgium, Canada, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Netherlands, Norway, Saudi Arabia, Singapore, South Korea, Spain, Taiwan, United Kingdom
Intervention Typesgenetic
Study TypeInterventional
Intervention ModelSingle Group
Healthy VolunteersNo
Condition TermsLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Completion Date2039-04-18
Lead Sponsor ClassIndustry
Eligibility SexAll

Eligibility Criteria

Inclusion Criteria:

  • All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
  • Patients who have provided informed consent for the long term follow up study prior to their study participation .

Exclusion Criteria:

  • There are no specific exclusion criteria for this study.

Identifiers & revision